This Week in Psychedelics
Jul 1, 2026
•
5 min read
[5-min read] The entropic brain hypothesis holds up as a model for conscious states.
Jun 24, 2026
[5-min read] Definium shares topline Phase 3 results for LSD in depression.
Jun 17, 2026
[5-min read] Personality type may predict the intensity of acute psychedelic effects.
Jun 10, 2026
[5-min read] 5-MeO-DMT delivers 100% remission in small postpartum depression trial.
Jun 3, 2026
[5-min read] Study investigates the link between psychedelics and mania.
May 27, 2026
6 min read
[5-min read] New study suggests psilocybin can significantly reduce neuropathic pain.
May 20, 2026
[5-min read] Two new studies weigh psychedelics as interventions for suicidality.
May 13, 2026
[5-min read] New study captures human brain changes after first psilocybin trip.
May 6, 2026
[5-min read] New study compares 2C-B to psilocybin and MDMA in healthy volunteers.
Apr 29, 2026
[5-min read] FDA awards priority vouchers to Compass, Otsuka, and Usona.
Apr 22, 2026
[5-min read] Trump signs executive order to accelerate psychedelic research and access.
Apr 15, 2026
12 min read
[5-min read] New study examines MDMA's effects on male reproductive biology.
Apr 8, 2026
[5-min read] Texas plans to move ibogaine initiative forward without a drug company.
Apr 1, 2026
13 min read
[5-min read] Otsuka agrees to acquire Transcend Therapeutics for $1.225 billion.
Mar 25, 2026
[5-min read] 24-trial review suggests psychedelics are no more effective than antidepressants.
Mar 18, 2026
[5-min read] One dose of psilocybin beats nicotine patches by a factor of six.
Mar 11, 2026
[5-min read] New study suggests psilocybin and MDMA repair myelin.
Mar 4, 2026
[5-min read] RAND report estimates 23% of U.S. adults support legalizing psilocybin.
Feb 25, 2026
[5-min read] FDA designates luvesilocin a breakthrough therapy.
Feb 18, 2026
[5-min read] Compass shares results from second Phase 3 psilocybin trial.
Feb 11, 2026
[5-min read] Pilot program brings at-home ketamine-assisted therapy to hospice patients.
Feb 4, 2026
[5-min read] Preclinical research shows low-dose psilocybin reverses metabolic disease.
Jan 28, 2026
[5-min read] RAND study projects 10 million Americans microdosed in 2025.
Jan 21, 2026
[5-min read] WHO data suggests severe adverse events from psychedelics are rare.
Jan 14, 2026
[5-min read] FDA accepts Compass Pathways' application to test psilocybin for PTSD.
